Real-world evaluation of the positive predictive value and transmission burden of a novel implantable cardiac monitor with a remote reprogramming capability: insights from a single-center experience
Background Implantable cardiac monitors (ICMs) are widely used for long-term arrhythmia surveillance but are often limited by a high false-positive alert rate, increasing the workload for device clinics. The LUX-Dx™ ICM incorporates dual-stage detection algorithms and remote reprogramming features designed to improve diagnostic accuracy and workflow efficiency. Objective To assess the real-world performance of the LUX-Dx™ ICM across all detectable arrhythmias, evaluating positive predictive value (PPV), transmission burden, and the impact of remote reprogramming. Methods We retrospectively analyzed 133 consecutive patients who received a LUX-Dx™ ICM between July 2023 and October 2024 with follow-up data collected through June 2025. Device episodes and transmissions were reviewed over a median 13-month follow-up. PPV was calculated at both patient- and episode-levels. Changes in PPV before and after remote reprogramming were also assessed. Results A total of 55,064 episodes and 5,192 transmissions were recorded (4.0 episodes and 1.2 transmissions per patient-month). Overall patient-level PPV was 87% (110/126), highest for bradycardia (100%) and lowest for pauses (71%). Overall, 93 of 126 patients (74%) with adjudicated episodes had at least one false-positive detection during follow-up. Episode-level PPV was 82% (95% CI: 82−83). Remote reprogramming was performed in 34% of patients and was associated with a descriptive increase in episode-level PPV (from 77% to 87%). Review strategies focusing on the first, longest, or fastest episode per transmission yielded comparable PPVs. Conclusions In routine clinical practice, the LUX-Dx™ ICM demonstrated favorable positive predictive value. Remote reprogramming enabled individualized optimization of detection parameters, although its potential impact on detection performance requires further investigation.
Authors
- Samir Fareh (ORCID: https://orcid.org/0009-0009-3539-4680)
- Sergio Valsecchi (ORCID: https://orcid.org/0000-0001-7055-6942)
- Mathieu Montoy
- Monica Campari (ORCID: https://orcid.org/0009-0009-7766-8109)
- Emilie Said
- Paul Charles
Institutions
- Boston Scientific (United States) (US)
- Hôpital de la Croix-Rousse (FR)
- Hospices Civils de Lyon (FR)
Publication Details
- Journal
- Frontiers in Cardiovascular Medicine
- Published
- 2026-11-20
- DOI
- https://doi.org/10.3389/fcvm.2026.2008276
- Primary Topic
- Cardiac pacing and defibrillation studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00